Noxopharm Ltd has released a press release.
Noxopharm Enhances Cash Position via R&D Rebate
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Earlier from Noxopharm
- Noxopharm 2023 AGM Corporate Presentation
- mRNA Vaccine Enhancer Shows Inflammation Reduction
- September 2023 Activities Report and Appendix 4C
- Response to ASX Query
- US FDA grants Orphan Drug Designation for CRO-67
Later from Noxopharm
- December 2023 Quarterly Activities Report and Appendix 4C
- Appendix 4D and Half Year 2024 Financial Report
- March 2024 Quarterly Activities Report and Appendix 4C
- June 2024 Quarterly Activities Report and Appendix 4C
- Significant CRO-67 Results in Pancreatic Cancer Studies
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm